XORTX Closes $3M Purchase of VB4-P5 Kidney Anti-Fibrotic Program
XORTX Therapeutics has closed the $3.0 million acquisition of the VB4-P5 kidney anti-fibrotic asset, issuing 154,544 common shares at US$3.5432 and 692,150 pre-funded warrants exercisable at US$0.0001. The pre-IND small molecule targets chronic kidney disease fibrosis and holds patent protection in over 30 jurisdictions.
1. Acquisition Details
On April 13, 2026, XORTX Therapeutics finalized the acquisition of the Vectus kidney anti-fibrotic program for an aggregate consideration of US$3.0 million. The company issued 154,544 common shares at a deemed price of US$3.5432 and 692,150 pre-funded warrants at US$3.5431 exercisable at US$0.0001, with warrant expiration on April 13, 2031 and a 9.99% ownership cap for Vectus.
2. VB4-P5 Asset Profile
The acquired VB4-P5 program is a novel small molecule at the pre-IND stage targeting fibrosis in rare and prevalent forms of chronic kidney disease. Assets include a comprehensive patent family covering composition-of-matter and method-of-use claims across more than 30 jurisdictions, along with associated regulatory documentation and manufacturing data.
3. Strategic Implications
The addition of VB4-P5 broadens XORTX's pipeline beyond its gout and ADPKD candidates, enhancing its focus on progressive kidney disease. By targeting fibrosis—a key driver of CKD progression in an addressable market exceeding 10 million patients—the company positions itself to develop a first-in-class anti-fibrotic therapy.